Susceptibility of pediatric HIV-1 isolates to recombinant CD4-IgG2 (PRO 542) and humanized mAb to the chemokine receptor CCR5 (PRO 140)

Journal of Allergy and Clinical Immunology

Volumn 118, Issue 2, 2006, Pages 518-521

  Shearer, William T ^a   DeVille, Jaime G ^b   Samson, Pearl M ^c   Moye Jr , John H ^d   Fletcher, Courtney V ^e   Church, Joseph A ^f   Spiegel, Hans M L ^g   Palumbo, Paul ^h   Fenton, Terence ^c   Smith, M Elizabeth ⁱ   Graham, Bobbie ^j   Kraimer, Joyce M ^k   Olson, William C ^l  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f CHILDREN S HOSPITAL LOS ANGELES   (United States)

^g CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^h UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

ⁱ NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^j FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^k SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^l A Subsidiary of Lantheus Holdings   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CD4 IMMUNOGLOBULIN G2; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; ENFUVIRTIDE; PRO 140; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ANTIVIRAL ACTIVITY; CD4+ T LYMPHOCYTE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION COEFFICIENT; CROSS RESISTANCE; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VITRO STUDY; KRUSKAL WALLIS TEST; LETTER; LYMPHOCYTE COUNT; MALE; MULTIPLE DRUG DOSE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; UNIVARIATE ANALYSIS; VIROGENESIS; VIRUS ISOLATION;

ANTIBODIES, MONOCLONAL; CD4 IMMUNOADHESINS; CHILD; CHILD, PRESCHOOL; HIV ANTIBODIES; HIV-1; HUMANS; RECEPTORS, CCR5;

EID: 33746571624     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2006.03.028     Document Type: Letter

References (11)

1. Hammer S.M. Clinical practice. Management of newly diagnosed HIV infection. N Engl J Med 353 (2005) 1702-1710
2. Castagna A., Biswas P., Beretta A., and Lazzarin A. The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development. Drugs 65 (2005) 879-904
3. Jacobson J.M., Israel R.J., Lowy I., Ostrow N.A., Vassilatos L.S., Barish M., et al. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor PRO 542. Antimicrob Agents Chemother 48 (2004) 423-429
4. Shearer W.T., Israel R.J., Starr S., Fletcher C.V., Wara D., Rathore M., et al. Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team. J Infect Dis 182 (2000) 1774-1779
5. Trkola A., Ketas T.J., Nagashima K.A., Zhao L., Cilliers T., Morris L., et al. Potent, broad-spectrum inhibition of human immunodeficiency virus type 1 by the CCR5 monoclonal antibody PRO 140. J Virol 75 (2001) 579-588
6. Cilliers T., Nhlapo J., Coetzer M., Orlovic D., Ketas T., Olson W.C., et al. The CCR5 and CXCR4 coreceptors are both used by human immunodeficiency virus type 1 primary isolates from subtype C. J Virol 77 (2003) 4449-4456
7. Rusert P., Kuster H., Joos B., Misselwitz B., Gujer C., Leemann C., et al. Virus isolates during acute and chronic human immunodeficiency virus type 1 infection show distinct patterns of sensitivity to entry inhibitors. J Virol 79 (2005) 8454-8469
8. Olson WC, Doshan H, Zhan C, Mezzatesta J, Assumma A, Czarnecky R, et al. New antiretroviral agents and approaches: clinical studies. 13th Conference on Retroviruses and Opportunistic Infections, Denver, Colo, February 5-9, 2006. Available at: http://www.retroconference.org/2006/.
9. Liossis S.N., and Tsokos G.C. Monoclonal antibodies and fusion proteins in medicine. J Allergy Clin Immunol 116 (2005) 721-729
10. Moyle G.J., Wildfire A., Mandalia S., Mayer H., Goodrich J., Whitcomb J., et al. Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis 191 (2005) 866-872
11. Kitchen C.M., Philpott S., Burger H., Weiser B., Anastos K., and Suchard M.A. Evolution of human immunodeficiency virus type 1 coreceptor usage during antiretroviral Therapy: a Bayesian approach. J Virol 78 (2004) 11296-11302